UCB shares fall despite guidance upgrade as CEO flags higher H2 costs
By Lucie Barbier and Margaux Perrin July 30 (Reuters) – Belgian biopharmaceutical group UCB raised its 2026 earnings guidance on Thursday, but its shares fell more than 8% as investors questioned whether some of the first-half earnings outperformance could be repeated in the second half. Adjusted EBITDA is now expected to grow in the mid-teens to low-twenties percentage range at constant exchange rates, up from a previous forecast of high single-digit to mid-teens growth.
How this was made
The 30-second read
Why it matters
The key trade is whether the market’s implied H2 EBITDA concern is temporary phasing or a genuine deterioration in underlying earnings power.
Market read
Investors are trading the credibility of UCB’s guidance, with the stock move driven by implied weaker H2 EBITDA versus expectations despite an overall guidance upgrade.
What to watch
Legacy product strength and the raised peak sales guidance for Bimzelx may offset H2 cost pressure more than the market is assuming.
Background
UCB previously narrowed guidance in April to absorb acquisition-related costs, and now upgrades 2026 EBITDA growth while acknowledging higher second-half clinical development spending.
Ticker impact
UCB raised 2026 adjusted EBITDA guidance to mid-teens to low-twenties growth, but shares fell 8.5% on concerns H2 won’t match H1.
Near-term downside bias as investors reprice the likelihood of sustained H1 outperformance into H2.
The article links the stock drop directly to analysts’ inference that implied H2 EBITDA is below expectations, reinforced by CEO commentary on higher H2 costs and non-recurring H1 drivers.
Market effects
Signals heightened scrutiny on biopharma guidance quality, especially whether outperformance is timing-related versus underlying demand and cost control.
May pressure other European biopharma names if investors generalize the ‘H2 cost step-up’ concern.
Limited spillover beyond European biotech, unless peers face similar clinical-development phasing and guidance credibility issues.
Counterpoint
The guidance raise could still be credible if investors focus on portfolio durability and physician confidence rather than phasing effects.
Key entities
- companyUCB
Belgian biopharmaceutical group that raised 2026 adjusted EBITDA guidance but saw shares drop on concerns about H2 cost and non-repeating H1 factors.
- personJean-Christophe Tellier
UCB CEO who said some first-half supporting elements will not replicate in the second half and that clinical development spending will be higher.
- productBimzelx
UCB anti-inflammatory drug; peak sales guidance raised to 7 billion euros, while first-half sales were slightly below expectations.
